They discovered that thymidylate synthase (TS), which was a potential predictive marker for treatment efficacy with pemetrexed, did not significantly change in rebiopsied lung tumors compared to primary tumors in 65 NSCLC patients taking after preoperative carboplatin and paclitaxel [8]. The gene discussed is TYMS; the disease is non-small cell lung carcinoma.